Author:
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Burza S , Croft SL , Boelaert M , 2018. Leishmaniasis. Lancet 392: 951–970.
-
2.
Pagliano P , Ascione T , Di Flumeri G , Boccia G , De Caro F , 2016. Visceral leishmaniasis in immunocompromised: diagnostic and therapeutic approach and evaluation of the recently released IDSA guidelines. Infez Med 24: 265–271.
-
3.
Fernández-Guerrero ML , Robles P , Rivas P , Mójer F , Muñíz G , de Górgolas M , 2004. Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop 90: 11–16.
-
4.
Pittalis S , Nicastri E , Spinazzola F , Ghirga P , De Marco M , Paglia MG , Narciso P , 2006. Leishmania infantum leishmaniasis in corticosteroid–treated patients. BMC Infect Dis 6: 177.
-
5.
Valdés Delgado T , Cordero Ruiz P , Bellido Muñoz F , 2017. Visceral leishmaniasis infection in a patient with Crohn’s disease treated with azathioprine. J Crohn’s Colitis 11: 1282–1283.
-
6.
Bosch-Nicolau P , Ubals M , Salvador F , Sánchez-Montalvá A , Aparicio G , Erra A , Martinez de Salazar P , Sulleiro E , Molina I , 2019. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression. PLoS Negl Trop Dis 13: e0007708.
-
7.
Clemente WT , Mourão PHO , Lopez-Medrano F , Schwartz BS , García-Donoso C , Torre-Cisneros J , 2018. Visceral and cutaneous leishmaniasis recommendations for solid organ transplant recipients and donors. Transplantation 102 (2S Suppl 2):S8–S15.
-
8.
Tintore M , Vidal-Jordana A , Sastre-Garriga J , 2019. Treatment of multiple sclerosis—success from bench to bedside. Nat Rev Neurol 15: 53–58.
-
9.
Groves A , Kihara Y , Chun J , 2013. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 328: 9–18.
-
10.
Winkelmann A , Loebermann M , Reisinger EC , Hartung HP , Zettl UK , 2016. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 12: 217–233.
-
11.
Artemiadis AK , Nikolaou G , Kolokythopoulos D , Tegos N , Terentiou A , Triantafyllou N , Papanastasiou I , 2015. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient. Mult Scler 21: 795–796.
-
12.
Hernández Clares R , Sánchez Pedreño P , García Vazquez E , Carreón Guarnizo E , Meca Lallana JE , 2018. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod. Leishmaniasis cutánea agresiva en paciente con esclerosis múltiple tratada con fingolimod. Neurologia 33: 348–349 (Engl Ed).
-
13.
Williams E , Isles NS , Seemann T , Kilpatrick T , Grigg A , Leroi M , Howden BP , Kwong JC , 2020. Case report: confirmation by metagenomic sequencing of visceral leishmaniasis in an immunosuppressed returned traveler. Am J Trop Med Hyg 103: 1930–1933.
-
14.
Motta AC , Arruda D , Souza CS , Foss NT , 2003. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid. Int J Dermatol 42: 703–706.
-
15.
Tejura N , Kim E , Dever LL , Chew D , 2019. Case report: mucocutaneous leishmaniasis masquerading as idiopathic midline granulomatous disease. Am J Trop Med Hyg 101: 1107–1110.
-
16.
Informe de posicionamiento terapéutico de alemtuzumab (Lemtrada®) , 2015. Available at: http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-alemtuzumab-lemtrada.pdf. Accessed June 4, 2021.
-
17.
Pitini V , Cascio A , Arrigo C , Altavilla G , 2012. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol 156: 1.
-
18.
Casabianca A , Marchetti M , Zallio F , Feyles E , Concialdi E , Ferroglio E , Biglino A , 2011. Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment. Infection 39: 375–378.
-
19.
Los-Arcos I , Aguilar-Company J , Ruiz-Camps I , 2020. Risk of infection associated with new therapies for lymphoproliferative syndromes. Riesgo de infección asociada a nuevas terapias para el tratamiento de los síndromes linfoproliferativos. Med Clin (Barc) 154: 101–107.
-
20.
Mattner J , Wandersee-Steinhäuser A , Pahl A , Röllinghoff M , Majeau GR , Hochman PS , Bogdan C , 2004. Protection against progressive leishmaniasis by IFN-beta. J Immunol 172: 7574–7582.
-
21.
Kumar R et al., 2020. Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral leishmaniasis. Cell Rep 30: 2512–2525.e9.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 4208 | 1868 | 118 |
| Full Text Views | 247 | 9 | 0 |
| PDF Downloads | 128 | 10 | 0 |
Case Report: Leishmaniasis in a 33-Year-Old Man with Multiple Sclerosis
Alvaro Guerra-Amor
Alvaro Guerra-Amor
Dermatology Department, Hospital Universitari Vall d’Hebrón, Barcelona, Spain;
Search for other papers by Alvaro Guerra-Amor in
Current site
Google Scholar
PubMed
Search for other papers by Alvaro Guerra-Amor in
Current site
Google Scholar
PubMed
Ane Lopez-Gonzalez
Ane Lopez-Gonzalez
Pneumology Department, Hospital Universitari Vall d’Hebrón, Barcelona, Spain;
Search for other papers by Ane Lopez-Gonzalez in
Current site
Google Scholar
PubMed
Search for other papers by Ane Lopez-Gonzalez in
Current site
Google Scholar
PubMed
Pau Bosch-Nicolau
Pau Bosch-Nicolau
Tropical Medicine & International Health Unit Vall d’Hebrón—Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d’Hebron, Barcelona, Spain;
Search for other papers by Pau Bosch-Nicolau in
Current site
Google Scholar
PubMed
Search for other papers by Pau Bosch-Nicolau in
Current site
Google Scholar
PubMed
Breogan Rodriguez-Acevedo
Breogan Rodriguez-Acevedo
Neurology-Neuroimmunology Service, Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain;
Search for other papers by Breogan Rodriguez-Acevedo in
Current site
Google Scholar
PubMed
Search for other papers by Breogan Rodriguez-Acevedo in
Current site
Google Scholar
PubMed
Ana Zabalza
Ana Zabalza
Neurology-Neuroimmunology Service, Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain;
Search for other papers by Ana Zabalza in
Current site
Google Scholar
PubMed
Search for other papers by Ana Zabalza in
Current site
Google Scholar
PubMed
Elena Sulleiro
Elena Sulleiro
Microbiology Department, University Hospital Vall d’Hebrón, Barcelona, Spain
Search for other papers by Elena Sulleiro in
Current site
Google Scholar
PubMed
Search for other papers by Elena Sulleiro in
Current site
Google Scholar
PubMed
Juan Espinosa-Pereiro
Juan Espinosa-Pereiro
Tropical Medicine & International Health Unit Vall d’Hebrón—Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d’Hebron, Barcelona, Spain;
Search for other papers by Juan Espinosa-Pereiro in
Current site
Google Scholar
PubMed
Search for other papers by Juan Espinosa-Pereiro in
Current site
Google Scholar
PubMed
Maria Luisa Aznar
Maria Luisa Aznar
Tropical Medicine & International Health Unit Vall d’Hebrón—Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d’Hebron, Barcelona, Spain;
Search for other papers by Maria Luisa Aznar in
Current site
Google Scholar
PubMed
Search for other papers by Maria Luisa Aznar in
Current site
Google Scholar
PubMed
Fernando Salvador
Fernando Salvador
Tropical Medicine & International Health Unit Vall d’Hebrón—Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d’Hebron, Barcelona, Spain;
Search for other papers by Fernando Salvador in
Current site
Google Scholar
PubMed
Search for other papers by Fernando Salvador in
Current site
Google Scholar
PubMed
Adrián Sánchez-Montalvá
Adrián Sánchez-Montalvá
Tropical Medicine & International Health Unit Vall d’Hebrón—Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d’Hebron, Barcelona, Spain;
Search for other papers by Adrián Sánchez-Montalvá in
Current site
Google Scholar
PubMed
Search for other papers by Adrián Sánchez-Montalvá in
Current site
Google Scholar
PubMed
Israel Molina
Israel Molina
Tropical Medicine & International Health Unit Vall d’Hebrón—Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d’Hebron, Barcelona, Spain;
Search for other papers by Israel Molina in
Current site
Google Scholar
PubMed
Search for other papers by Israel Molina in
Current site
Google Scholar
PubMed
ABSTRACT.
Leishmaniasis is a protozoan disease caused by species of genus Leishmania. Immunosuppression increases the risk of severe clinical forms and impairs response to treatment. The expansion of the use of immunomodulatory drugs for different conditions has raised the number of these cases. In this report, we present a case of visceral leishmaniasis in a patient with multiple sclerosis (MS) under fingolimod treatment. He presented with the triad of fever, visceromegaly, and pancytopenia and was diagnosed by the presence of amastigotes in a bone marrow sample. Furthermore, we discuss the previous published cases of MS patients under different immunosuppressant therapies to highlight its risk in endemic areas and suggest a therapeutic approach.
Author Notes
These authors contributed equally to this work.
Authors’ addresses: Alvaro Guerra-Amor, Dermatology Department, Hospital Universitari Vall d’Hebrón, Barcelona, Spain, E-mail: aguerraamor@gmail.com. Ane Lopez-Gonzalez, Pneumology Department, Hospital Universitari Vall d’Hebrón, Barcelona, Spain, E-mail: anelopez95@gmail.com. Pau Bosch-Nicolau, Juan Espinosa-Pereiro, Maria Luisa Aznar, Fernando Salvador, Adrián Sánchez-Montalvá, and Israel Molina, Tropical Medicine & International Health Unit Vall d’Hebrón - Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d’Hebron, Barcelona, Spain, E-mails: pau.boschnicolau@gmail.com, juan.espinosa.pereiro@outlook.es, mlaznar@vhebron.net, fmsalvador@vhebron.net, adriansanchezmontalva@gmail.com, and israelmolina@ymail.com. Breogan Rodriguez-Acevedo and Ana Zabalza, Neurology-Neuroimmunology Service, Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, E-mails: brodriguez@cem-cat.org and azabalza@gmail.com. Elena Sulleiro, Microbiology Department, University Hospital Vall d’Hebrón, Barcelona, Spain, E-mail: esulleir@vhebron.net.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Burza S , Croft SL , Boelaert M , 2018. Leishmaniasis. Lancet 392: 951–970.
-
2.
Pagliano P , Ascione T , Di Flumeri G , Boccia G , De Caro F , 2016. Visceral leishmaniasis in immunocompromised: diagnostic and therapeutic approach and evaluation of the recently released IDSA guidelines. Infez Med 24: 265–271.
-
3.
Fernández-Guerrero ML , Robles P , Rivas P , Mójer F , Muñíz G , de Górgolas M , 2004. Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop 90: 11–16.
-
4.
Pittalis S , Nicastri E , Spinazzola F , Ghirga P , De Marco M , Paglia MG , Narciso P , 2006. Leishmania infantum leishmaniasis in corticosteroid–treated patients. BMC Infect Dis 6: 177.
-
5.
Valdés Delgado T , Cordero Ruiz P , Bellido Muñoz F , 2017. Visceral leishmaniasis infection in a patient with Crohn’s disease treated with azathioprine. J Crohn’s Colitis 11: 1282–1283.
-
6.
Bosch-Nicolau P , Ubals M , Salvador F , Sánchez-Montalvá A , Aparicio G , Erra A , Martinez de Salazar P , Sulleiro E , Molina I , 2019. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression. PLoS Negl Trop Dis 13: e0007708.
-
7.
Clemente WT , Mourão PHO , Lopez-Medrano F , Schwartz BS , García-Donoso C , Torre-Cisneros J , 2018. Visceral and cutaneous leishmaniasis recommendations for solid organ transplant recipients and donors. Transplantation 102 (2S Suppl 2):S8–S15.
-
8.
Tintore M , Vidal-Jordana A , Sastre-Garriga J , 2019. Treatment of multiple sclerosis—success from bench to bedside. Nat Rev Neurol 15: 53–58.
-
9.
Groves A , Kihara Y , Chun J , 2013. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 328: 9–18.
-
10.
Winkelmann A , Loebermann M , Reisinger EC , Hartung HP , Zettl UK , 2016. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 12: 217–233.
-
11.
Artemiadis AK , Nikolaou G , Kolokythopoulos D , Tegos N , Terentiou A , Triantafyllou N , Papanastasiou I , 2015. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient. Mult Scler 21: 795–796.
-
12.
Hernández Clares R , Sánchez Pedreño P , García Vazquez E , Carreón Guarnizo E , Meca Lallana JE , 2018. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod. Leishmaniasis cutánea agresiva en paciente con esclerosis múltiple tratada con fingolimod. Neurologia 33: 348–349 (Engl Ed).
-
13.
Williams E , Isles NS , Seemann T , Kilpatrick T , Grigg A , Leroi M , Howden BP , Kwong JC , 2020. Case report: confirmation by metagenomic sequencing of visceral leishmaniasis in an immunosuppressed returned traveler. Am J Trop Med Hyg 103: 1930–1933.
-
14.
Motta AC , Arruda D , Souza CS , Foss NT , 2003. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid. Int J Dermatol 42: 703–706.
-
15.
Tejura N , Kim E , Dever LL , Chew D , 2019. Case report: mucocutaneous leishmaniasis masquerading as idiopathic midline granulomatous disease. Am J Trop Med Hyg 101: 1107–1110.
-
16.
Informe de posicionamiento terapéutico de alemtuzumab (Lemtrada®) , 2015. Available at: http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-alemtuzumab-lemtrada.pdf. Accessed June 4, 2021.
-
17.
Pitini V , Cascio A , Arrigo C , Altavilla G , 2012. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol 156: 1.
-
18.
Casabianca A , Marchetti M , Zallio F , Feyles E , Concialdi E , Ferroglio E , Biglino A , 2011. Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment. Infection 39: 375–378.
-
19.
Los-Arcos I , Aguilar-Company J , Ruiz-Camps I , 2020. Risk of infection associated with new therapies for lymphoproliferative syndromes. Riesgo de infección asociada a nuevas terapias para el tratamiento de los síndromes linfoproliferativos. Med Clin (Barc) 154: 101–107.
-
20.
Mattner J , Wandersee-Steinhäuser A , Pahl A , Röllinghoff M , Majeau GR , Hochman PS , Bogdan C , 2004. Protection against progressive leishmaniasis by IFN-beta. J Immunol 172: 7574–7582.
-
21.
Kumar R et al., 2020. Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral leishmaniasis. Cell Rep 30: 2512–2525.e9.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 4208 | 1868 | 118 |
| Full Text Views | 247 | 9 | 0 |
| PDF Downloads | 128 | 10 | 0 |